Biomarkers of ischemia in patients with known coronary artery disease: Do interleukin-6 and tissue factor measurements during dobutamine stress echocardiography give additional insight?

Circulation

Volumn 112, Issue 21, 2005, Pages 3215-3217

  Christenson, Robert H ^a   DeFilippi, Christopher P ^a   Kreutzer, Donald ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Echocardiography; Editorials; Inflammation; Interleukins; Stress

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; DOBUTAMINE; INTERLEUKIN 6; THROMBOPLASTIN; TUMOR NECROSIS FACTOR;

BLOOD CLOTTING; CORONARY ARTERY DISEASE; EDITORIAL; FIBRINOLYSIS; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MEDIATOR RELEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRESS ECHOCARDIOGRAPHY; TARGET CELL; BLOOD; CORONARY ARTERY ATHEROSCLEROSIS; ECHOGRAPHY; METABOLISM; NOTE; PREDICTION AND FORECASTING;

BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; ECHOCARDIOGRAPHY, STRESS; HUMANS; INTERLEUKIN-6; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; THROMBOPLASTIN;

EID: 33644874935     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.581918     Document Type: Editorial

References (19)

1. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun. 2002;297:700-713.
2. Ikonomidis I, Athanassopoulos G, Lekakis J, Venetsanou K, Margarita Marinou M, Stamatelopoulos K, Cokkinos DV, Nihoyannopoulos P. Myocardial ischemia induces interleukin-6 and tissue factor production in patients with coronary artery disease: a dobutamine stress echocardiography study. Circulation. 2005;112:3272-3279.
3. Deng MC, Erren M, Lutgen A, Zimmermann P, Brisse B, Schmitz W, Assmann G, Breithardt G, Scheld H. Interleukin 6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure. Int J Cardiol. 1996;57:129-134.
4. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol. 2000;36:959-969.
5. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, Goormastic M, Pepoy ML, McErlean ES, Topol EJ, Nissen SE, Hazen SL. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604.
6. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029.
7. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-824.
8. Ruck A, Gustafsson T, Norrbom J, Nowak J, Kallner G, Soderberg M, Sylven C, Drvota V. ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun. 2004;322:287-291.
9. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
10. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol EJ, Simoons ML, Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies to Open Occluded Arteries (GUSTO)-IV substudy. Circulation. 2003;108:275-281.
11. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776-780.
12. Foote RS, Pearlman JD, Siegel AH, Yeo KT. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol. 2004;44:1980-1987.
13. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, Hall C, McCabe CH, Braunwald E. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004;44:1988-1995.
14. Asada J, Tsuji H, Iwasaka T, Thomas JD, Lauer MS. Usefulness of plasma brain natriuretic peptide levels in predicting dobutamine-induced myocardial ischemia. Am J Cardiol. 2004;93:702-704.
15. Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB, Harrington RA, Califf RM, Krucoff MW. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001;37:9-18.
16. Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. 2003;107:2403-2405.
17. Quiles J, Roy D, Gaze D, Garrido IP, Avanzas P, Sinha M, Kaski JC. Relation of ischemia-modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol. 2003;92:322-324.
18. Kleinfeld AM, Prothro D, Brown DL, Davis RC, Richieri GV, DeMaria A. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am J Cardiol. 1996;78:1350-1354.
19. Dagianti A, Penco M, Agati L, Sciomer S, Dagianti A, Rosanio S, Fedele F. Stress echocardiography: comparison of exercise, dipyridamole and dobutamine in detecting and predicting the extent of coronary artery disease. J Am Coll Cardiol. 1995;26:18-25.